e-learning
resources
ERJ
2009
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis?
Yew W. W., Chang K. C., Chau C. H.
Source:
Eur Respir J 2009; 34: 1492-1494
Journal Issue:
December
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Yew W. W., Chang K. C., Chau C. H.. What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis?. Eur Respir J 2009; 34: 1492-1494
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?
Source: Eur Respir J 2016; 48: 582-585
Year: 2016
Is adding fluoroquinolones to regimens for treating isoniazid-resistant tuberculosis necessary?
Source: Eur Respir J, 54 (4) 1901494; 10.1183/13993003.01494-2019
Year: 2019
Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis
Source: Eur Respir J 2013; 42: 504-512
Year: 2013
Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis
Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017
Year: 2017
Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India
Source: Eur Respir J 2012; 39: 956-962
Year: 2012
Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients
Source: Eur Respir J 2013; 42: 1614-1621
Year: 2013
Linezolid in multidrug-resistant tuberculosis treatment
Source: Eur Respir J 2004; 24: Suppl. 48, 485s
Year: 2004
Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience
Source: Eur Respir J 2016; 47: 333-336
Year: 2016
Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis
Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis
Year: 2008
The individual-tailored treatment regimens for multidrug-resistant tuberculosis
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Administration of linezolid, bedaquiline and imipenem in treatment of patients with extensively drug-resistant tuberculosis
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
A study on the clinical efficacy of a combination regimen with azithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 722s
Year: 2004
Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis
Source: Eur Respir J , 49 (3) 1601724; DOI: 10.1183/13993003.01724-2016
Year: 2017
The efficacy of a rifabutin-containing regimen for rifabutin-susceptible multidrug-resistant tuberculosis
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Clinical efficacy and safety of clarithromycin in the treatment of multi-drug resistant tuberculosis
Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance
Year: 2009
Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy
Source: Eur Respir J 2001; 17: 641-646
Year: 2001
Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis
Source: Eur Respir J, 57 (4) 2004454; 10.1183/13993003.04454-2020
Year: 2021
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases
Source: Eur Respir J 2008; 31: 1155-1159
Year: 2008
Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity?
Source: Eur Respir J, 49 (5) 1700738; 10.1183/13993003.00738-2017
Year: 2017
Management of multidrug-resistant tuberculosis and patients in retreatment
Source: Eur Respir J 2005; 25: 928-936
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept